PURPOSE:Patients 16 to 21 years of age with acute lymphoblastic leukemia (ALL) have an inferior outcome compared with younger children, leading some medical oncologists to advocate allogeneic stem-cell transplantation in first remission for these patients. We examined outcome for young adults with ALL enrolled onto the Children's Cancer Group (CCG) 1961 study between 1996 and 2002. PATIENTS AND METHODS: CCG 1961 entered patients with ALL 1 to 21 years of age with initial WBC count > or = 50,000/microL and/or age > or = 10 years. Randomly assigned therapies evaluated the impact of postinduction treatment intensification on outcome. We examined outcome and prognostic factors for 262 young adults with ALL. RESULTS: Five-year event-free and overall survival rates for young adult patients are 71.5% (SE, 3.6%) and 77.5% (SE, 3.3%), respectively. Rapid responder patients (< 25% bone marrow blasts on day 7) randomly assigned to augmented therapy had 5-year event-free survival of 81.8% (SE, 7%), as compared with 66.8% (SE, 6.7%) for patients receiving standard therapy (P = .07). One versus two interim maintenance and delayed intensification courses had no significant impact on event-free survival. WBC count more than 50,000/microL was an adverse prognostic factor. CONCLUSION:Young adult patients with ALL showing a rapid response to induction chemotherapy benefit from early intensive postinduction therapy but do not benefit from a second interim maintenance and delayed intensification phase. Given the excellent outcome with this chemotherapy, there seems to be no role for the routine use of allogeneic stem-cell transplantation in first remission for young adults with ALL.
RCT Entities:
PURPOSE:Patients 16 to 21 years of age with acute lymphoblastic leukemia (ALL) have an inferior outcome compared with younger children, leading some medical oncologists to advocate allogeneic stem-cell transplantation in first remission for these patients. We examined outcome for young adults with ALL enrolled onto the Children's Cancer Group (CCG) 1961 study between 1996 and 2002. PATIENTS AND METHODS: CCG 1961 entered patients with ALL 1 to 21 years of age with initial WBC count > or = 50,000/microL and/or age > or = 10 years. Randomly assigned therapies evaluated the impact of postinduction treatment intensification on outcome. We examined outcome and prognostic factors for 262 young adults with ALL. RESULTS: Five-year event-free and overall survival rates for young adult patients are 71.5% (SE, 3.6%) and 77.5% (SE, 3.3%), respectively. Rapid responder patients (< 25% bone marrow blasts on day 7) randomly assigned to augmented therapy had 5-year event-free survival of 81.8% (SE, 7%), as compared with 66.8% (SE, 6.7%) for patients receiving standard therapy (P = .07). One versus two interim maintenance and delayed intensification courses had no significant impact on event-free survival. WBC count more than 50,000/microL was an adverse prognostic factor. CONCLUSION: Young adult patients with ALL showing a rapid response to induction chemotherapy benefit from early intensive postinduction therapy but do not benefit from a second interim maintenance and delayed intensification phase. Given the excellent outcome with this chemotherapy, there seems to be no role for the routine use of allogeneic stem-cell transplantation in first remission for young adults with ALL.
Authors: J M de Bont; B van der Holt; A W Dekker; A van der Does-van den Berg; P Sonneveld; R Pieters Journal: Leukemia Date: 2004-12 Impact factor: 11.528
Authors: A Möricke; M Zimmermann; A Reiter; H Gadner; E Odenwald; J Harbott; W-D Ludwig; H Riehm; M Schrappe Journal: Klin Padiatr Date: 2005 Nov-Dec Impact factor: 1.349
Authors: J Nachman; H N Sather; J D Buckley; P S Gaynon; P G Steinherz; D G Tubergen; B C Lampkin; G D Hammond Journal: Cancer Date: 1993-05-15 Impact factor: 6.860
Authors: Sabine L A Plasschaert; Willem A Kamps; Edo Vellenga; Elisabeth G E de Vries; Eveline S J M de Bont Journal: Cancer Treat Rev Date: 2004-02 Impact factor: 12.111
Authors: J B Nachman; H N Sather; M G Sensel; M E Trigg; J M Cherlow; J N Lukens; L Wolff; F M Uckun; P S Gaynon Journal: N Engl J Med Date: 1998-06-04 Impact factor: 91.245
Authors: Wendy Stock; Mei La; Ben Sanford; Clara D Bloomfield; James W Vardiman; Paul Gaynon; Richard A Larson; James Nachman Journal: Blood Date: 2008-05-23 Impact factor: 22.113
Authors: V M Santana; R K Dodge; W M Crist; G K Rivera; A T Look; F G Behm; S C Raimondi; C H Pui Journal: Leukemia Date: 1990-02 Impact factor: 11.528
Authors: Ramya Ramanujachar; Sue Richards; Ian Hann; Anthony Goldstone; Christopher Mitchell; Ajay Vora; Jacob Rowe; David Webb Journal: Pediatr Blood Cancer Date: 2007-03 Impact factor: 3.167
Authors: T Sakura; F Hayakawa; I Sugiura; T Murayama; K Imai; N Usui; S Fujisawa; T Yamauchi; T Yujiri; K Kakihana; Y Ito; H Kanamori; Y Ueda; Y Miyata; M Kurokawa; N Asou; K Ohnishi; S Ohtake; Y Kobayashi; K Matsuo; H Kiyoi; Y Miyazaki; T Naoe Journal: Leukemia Date: 2017-09-15 Impact factor: 11.528
Authors: Ching-Hon Pui; Amar J Gajjar; Javier R Kane; Ibrahim A Qaddoumi; Alberto S Pappo Journal: Nat Rev Clin Oncol Date: 2011-06-28 Impact factor: 66.675
Authors: Stephen P Hunger; Mignon L Loh; James A Whitlock; Naomi J Winick; William L Carroll; Meenakshi Devidas; Elizabeth A Raetz Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167